ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Apr 18, 2023 12:00 JST
Source:
Avance Clinical
Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023
ADELAIDE, AUS & SAN DIEGO, Apr 18, 2023 - (ACN Newswire) - Avance Clinical the leading award-winning Australian and North American biotech CRO that offers a GlobalReady program to early phase biotech companies to speed up the path to regulatory approval, has been invited to join the Evolution Europe Summit 2023 (Montreux, Switzerland 20 April - 21 April 2023). The panel discussion is focused on the evolution of clinical trials including technology, DCTs, reducing time and cost, drug development planning for approvals, and scaling globally in later phases.
Avance Clinical CEO, Yvonne Lungershausen has been invited to share the Australian and US CRO experience and future projections with a focus on patient centricity and Decentralized Clinical Trials (DCTs) at the Evolution Europe Summit 2023.
Avance Clinical was recently identified by GlobalData as a global leader in DCT technology.
The Evolution Summit is an invitation-only, premium forum bringing leading clinical research executives and innovative solution providers. The summit's content is aligned with key clinical R&D challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers. See full details here.
https://www.april23.evolution-summit.com/
Avance Clinical has recently been ranked as the world leader in DCT technology adoption by GlobalData and Clinical Trial Arena in the CRO sector. The report found 46% of Avance Clinical's trials incorporated some elements of DCT technologies in 2022 including telemedicine, remote monitoring, and digital data collection.
The DCT report also noted that Avance Clinical's staff training in the latest technologies was a key factor in the ranking. See the full report here.
https://www.clinicaltrialsarena.com/features/year-in-review-dct-2022/
Avance Clinical's unique clinical offering GlobalReady enables biotechs that have completed early to mid-phases in Australia to rapidly and seamlessly transition to the US in preparation for FDA approvals, all with the one CRO and dedicated teams across both regions, which reduces time and cost and delivers quality data.
There are currently more than 280 Phase III global trials that have conducted their Phase I study in Australia, which demonstrates Australian data acceptability with the FDA and other major regulatory authorities.
More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program.
This seamless GlobalReady journey is designed so biotechs can:
- Take advantage of the Australian early-phase clinical trial landscape (No IND and 43.5% tax rebate)
- Transition or expand into North America for later phases - without changing CROs (retain study knowledge and processes/team)
- Seamlessly operationalize global dose-escalation and dose-expansion trials across the two regions
- Harness significant speed and cost advantages
- Be assured of quality data - transferable and readily acceptable by the FDA and other regulatory authorities
Find out more:
- Learn about the Australian Advantage here.
https://www.avancecro.com/the-australian-advantage/
- Learn about the GlobalReady model here.
https://www.avancecro.com/avance-clinical-north-america-operations/
- For more information about the benefits of running your next study with Avance Clinical contact us:
enquiries@avancecro.com
About Avance Clinical
Avance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services. www.avancecro.com
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past three years, has been providing CRO services in the region for more than 24 years.
Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold-standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.
Media Contact:
Avance Clinical
Kate Thompson
media@avancecro.com
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2023 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Delica Mini Wins 2023-2024 Japan Car of the Year Design Award
Dec 08, 2023 21:07 JST
Space Compass, NTT DOCOMO, NTT and SKY Perfect JSAT to Develop Direct-to-Device Service via Space-based Non-terrestrial Network
Dec 08, 2023 17:34 JST
MHI and ADNOC Sign Agreement to Explore Low Carbon Collaboration Opportunities to Build Blue NH3 and Blue H2 Value Chains
Dec 08, 2023 17:22 JST
MHI and Mitsubishi Logisnext Receive First Order from Kirin Group for an Automated Picking Solution
Dec 08, 2023 17:09 JST
Macau LRT Barra Extension Line Begins Commercial Operations on December 8
Dec 08, 2023 17:07 JST
Fujitsu and Palantir to strengthen strategic partnership to solve societal challenges and accelerate business transformation globally
Dec 08, 2023 16:28 JST
Honda to Begin Sales of Refreshed Odyssey in Japan
Dec 07, 2023 16:30 JST
Honda to Premiere New EV Series for Global Markets at CES 2024
Dec 07, 2023 13:00 JST
Vesica AI Selected as Winner of Inaugural Olympus Asia Pacific Innovation Program
Dec 07, 2023 11:00 JST
Hitachi High-Tech Launches Dark Field Wafer Defect Inspection System DI4600 to Provide High Throughput and High-Precision Defect Detection on Patterned Wafers
Dec 06, 2023 17:38 JST
Fujitsu optimizes installation of EV charging infrastructure in India with Fujitsu Fleet Optimization solution trial
Dec 06, 2023 11:02 JST
Fujitsu Finland to provide comprehensive IT services to Kempower, provider of electric vehicle fast charging solutions
Dec 05, 2023 10:52 JST
DENSO Announces Organizational and Executive Changes
Dec 04, 2023 18:12 JST
All-New Triton Earns Top Rating in 2023 ASEAN NCAP
Dec 04, 2023 17:07 JST
Fujitsu and KDDI Research successfully implement large-capacity multiband wavelength multiplexing transmission with installed optical fiber
Dec 04, 2023 10:34 JST
GC Collaborates with MHI to explore the utilization of hydrogen, ammonia and CCS technology to develop a large-scale petrochemical plant to achieve Net Zero
Dec 01, 2023 17:22 JST
NEC named among IAM's 2023 Asia IP Elite
Dec 01, 2023 14:50 JST
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand
Nov 30, 2023 16:25 JST
Boosting Growth Investment to Power Mobility Company Transformation Toyota-DENSO Capital Ties Revised
Nov 30, 2023 16:17 JST
Olympus's Net-Zero Targets Approved by SBTi
Nov 30, 2023 11:00 JST
More Latest Release >>
Related Release
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
Avance Clinical Joins Global Health Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies
May 25 2023 09:00 JST
Avance Clinical Celebrates GlobalReady Success as 40 Biotechs Join Program
January 11 2023 15:00 JST
Avance Clinical Wins International Health Award for Biotech CRO Services
September 28 2022 16:00 JST
Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs
September 06 2022 13:00 JST
Avance Clinical Sponsors Biotech Company of the Year Awards at Informa Pharma Intelligence Awards 2022
August 29 2022 18:00 JST
Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 - Best Contract Research Organization in APAC
April 19 2022 10:00 JST
Avance Clinical Announces New Office Opening in Melbourne
March 31 2022 15:00 JST
Avance Clinical Announces New Office Opening in Sydney
March 02 2022 15:00 JST
More Press release >>